<document id="DDI-MedLine.d99">
    <sentence id="DDI-MedLine.d99.s0" text="Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.&#10;">
        <entity charOffset="0-10" id="DDI-MedLine.d99.s0.e0" text="Fluvoxamine" type="drug" />
        <entity charOffset="63-73" id="DDI-MedLine.d99.s0.e1" text="tolbutamide" type="drug" />
        <pair ddi="true" e1="DDI-MedLine.d99.s0.e0" e2="DDI-MedLine.d99.s0.e1" id="DDI-MedLine.d99.s0.p0" type="mechanism" />
    </sentence>
    <sentence id="DDI-MedLine.d99.s3" text="In period A, all volunteers took 500 mg of tolbutamide orally. ">
        <entity charOffset="43-53" id="DDI-MedLine.d99.s3.e0" text="tolbutamide" type="drug" />
    </sentence>
    <sentence id="DDI-MedLine.d99.s5" text="Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). ">
        <entity charOffset="42-52" id="DDI-MedLine.d99.s5.e0" text="fluvoxamine" type="drug" />
    </sentence>
    <sentence id="DDI-MedLine.d99.s6" text="The groups then took 500 mg of tolbutamide as a single dose (day 0). ">
        <entity charOffset="31-41" id="DDI-MedLine.d99.s6.e0" text="tolbutamide" type="drug" />
    </sentence>
    <sentence id="DDI-MedLine.d99.s9" text="RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. ">
        <entity charOffset="31-41" id="DDI-MedLine.d99.s9.e0" text="fluvoxamine" type="drug" />
        <entity charOffset="131-141" id="DDI-MedLine.d99.s9.e1" text="tolbutamide" type="drug" />
        <pair ddi="true" e1="DDI-MedLine.d99.s9.e0" e2="DDI-MedLine.d99.s9.e1" id="DDI-MedLine.d99.s9.p0" type="mechanism" />
    </sentence>
    <sentence id="DDI-MedLine.d99.s10" text="There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. ">
        <entity charOffset="110-120" id="DDI-MedLine.d99.s10.e0" text="tolbutamide" type="drug" />
    </sentence>
    <sentence id="DDI-MedLine.d99.s12" text="Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. ">
        <entity charOffset="119-129" id="DDI-MedLine.d99.s12.e0" text="fluvoxamine" type="drug" />
    </sentence>
    <sentence id="DDI-MedLine.d99.s13" text="CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.">
        <entity charOffset="12-22" id="DDI-MedLine.d99.s13.e0" text="Fluvoxamine" type="drug" />
    </sentence>
</document>